News

News Archive

Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor)

Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor)

NEWTON, Mass. and FLORENCE, Italy, – February 21st, 2023 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer...
Menarini Group are with the Turkish and Syrian populations

Menarini Group are with the Turkish and Syrian populations

The hearts and thoughts of the Menarini Group are with the Turkish and Syrian populations affected by the recent and devastating earthquake. All our employees and their families can...
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations

Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations

FLORENCE (Italy) and New York City (U.S.) January 30th, 2023 – The Menarini Group (“Menarini”), a leading Italian pharmaceutical and diagnostics company, announced...

Select a Year from the Archive

Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Follow our blog

Discover our stories from all over the world

Read More